Corbus Pharmaceuticals Holdings Inc - ESG Rating & Company Profile powered by AI
Browse to the bottom of this webpage for potential risks for Corbus Pharmaceuticals Holdings Inc based on industry, location and size. The webpage displays a zero-cost E,S&G assessment for Corbus Pharmaceuticals Holdings Inc. This ESG score covers 17 United Nations Sustainable Development Goals including: 'Zero Hunger', 'Sustainable Cities & Communities' and 'Life below Water'.
Corbus Pharmaceuticals Holdings Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 2.7, social score of 3.2 and governance score of 6.0.
4.0
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
989 | Spectrum Pharmaceuticals Inc | 4.1 | High |
989 | Tricida Inc | 4.1 | High |
1004 | Corbus Pharmaceuticals Holdings Inc | 4.0 | High |
1004 | Can B Corp | 4.0 | High |
1004 | CLS Holdings USA Inc | 4.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Corbus Pharmaceuticals Holdings Inc have an accelerator or VC vehicle to help deliver innovation?
Does Corbus Pharmaceuticals Holdings Inc disclose current and historical energy intensity?
Does Corbus Pharmaceuticals Holdings Inc report the average age of the workforce?
Does Corbus Pharmaceuticals Holdings Inc reference operational or capital allocation in relation to climate change?
Does Corbus Pharmaceuticals Holdings Inc disclose its ethnicity pay gap?
Does Corbus Pharmaceuticals Holdings Inc disclose cybersecurity risks?
Does Corbus Pharmaceuticals Holdings Inc offer flexible work?
Does Corbus Pharmaceuticals Holdings Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Corbus Pharmaceuticals Holdings Inc disclose the number of employees in R&D functions?
Does Corbus Pharmaceuticals Holdings Inc conduct supply chain audits?
Does Corbus Pharmaceuticals Holdings Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Corbus Pharmaceuticals Holdings Inc conduct 360 degree staff reviews?
Does Corbus Pharmaceuticals Holdings Inc disclose the individual responsible for D&I?
Does Corbus Pharmaceuticals Holdings Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Corbus Pharmaceuticals Holdings Inc disclose current and / or historical scope 2 emissions?
Does Corbus Pharmaceuticals Holdings Inc disclose water use targets?
Does Corbus Pharmaceuticals Holdings Inc have careers partnerships with academic institutions?
Did Corbus Pharmaceuticals Holdings Inc have a product recall in the last two years?
Does Corbus Pharmaceuticals Holdings Inc disclose incidents of discrimination?
Does Corbus Pharmaceuticals Holdings Inc allow for Work Councils/Collective Agreements to be formed?
Has Corbus Pharmaceuticals Holdings Inc issued a profit warning in the past 24 months?
Does Corbus Pharmaceuticals Holdings Inc disclose parental leave metrics?
Does Corbus Pharmaceuticals Holdings Inc disclose climate scenario or pathway analysis?
Does Corbus Pharmaceuticals Holdings Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Corbus Pharmaceuticals Holdings Inc disclose the pay ratio of women to men?
Does Corbus Pharmaceuticals Holdings Inc support suppliers with sustainability related research and development?
Does Corbus Pharmaceuticals Holdings Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Corbus Pharmaceuticals Holdings Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Corbus Pharmaceuticals Holdings Inc involved in embryonic stem cell research?
Does Corbus Pharmaceuticals Holdings Inc disclose GHG and Air Emissions intensity?
Does Corbus Pharmaceuticals Holdings Inc disclose its waste policy?
Does Corbus Pharmaceuticals Holdings Inc report according to TCFD requirements?
Does Corbus Pharmaceuticals Holdings Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Corbus Pharmaceuticals Holdings Inc disclose energy use targets?
Does Corbus Pharmaceuticals Holdings Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Corbus Pharmaceuticals Holdings Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Corbus Pharmaceuticals Holdings Inc
These potential risks are based on the size, segment and geographies of the company.
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.